| Name | Title | Contact Details |
|---|
Catalina Material Handling supplies an array of industrial storage and material handling products. Over the past thirty years, we have been supplying racking and storage services across the United States and Canada. Ranging from multiple warehouse racking structures to catwalk systems, Catalina MH also provides custom order racking to fit any clients storage needs. We provide many storage solutions and racking systems which includes: pallet racks, push-back, drive-in, cantilever, carton flow, multi-level pick rack, shelving, and mezzanine systems to meet the unique designs of our clients. We also offer Seismic Engineering and Project Management Services, including automated designs and detailed plans for each system to match our clients warehouse measurements and ensure optimal storage space. We evaluate each project diligently, ensuring that customer satisfaction is achieved. Automation by Catalina Material Handling provides software and automation solutions that reduces human errors, lowers operation costs, improves warehouse productivity, eliminates safety risks, optimizes space, reduces processing time, and strengthens customer satisfaction. Check out www.automationbycatalina.com for more information.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
RevGen GENIUS stands as a premier source for aiding businesses in crafting a robust and efficient go-to-market (GTM) strategy. With our expert guidance, clients can drive revenue growth with confidence.